BBIO
Price
$54.92
Change
-$0.11 (-0.20%)
Updated
Oct 17 closing price
Capitalization
10.5B
11 days until earnings call
ONC
Price
$316.42
Change
-$1.60 (-0.50%)
Updated
Oct 17 closing price
Capitalization
35.32B
25 days until earnings call
Interact to see
Advertisement

BBIO vs ONC

Header iconBBIO vs ONC Comparison
Open Charts BBIO vs ONCBanner chart's image
BridgeBio Pharma
Price$54.92
Change-$0.11 (-0.20%)
Volume$1.36M
Capitalization10.5B
BeOne Medicines
Price$316.42
Change-$1.60 (-0.50%)
Volume$333.84K
Capitalization35.32B
BBIO vs ONC Comparison Chart in %
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BBIO vs. ONC commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a Hold and ONC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (BBIO: $54.92 vs. ONC: $316.42)
Brand notoriety: BBIO and ONC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 62% vs. ONC: 112%
Market capitalization -- BBIO: $10.5B vs. ONC: $35.32B
BBIO [@Biotechnology] is valued at $10.5B. ONC’s [@Biotechnology] market capitalization is $35.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whileONC’s FA Score has 0 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • ONC’s FA Score: 0 green, 5 red.
According to our system of comparison, both BBIO and ONC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 6 TA indicator(s) are bullish while ONC’s TA Score has 3 bullish TA indicator(s).

  • BBIO’s TA Score: 6 bullish, 3 bearish.
  • ONC’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, BBIO is a better buy in the short-term than ONC.

Price Growth

BBIO (@Biotechnology) experienced а -1.03% price change this week, while ONC (@Biotechnology) price change was -1.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

BBIO is expected to report earnings on Oct 30, 2025.

ONC is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ONC($35.3B) has a higher market cap than BBIO($10.5B). BBIO YTD gains are higher at: 100.146 vs. ONC (71.306). ONC has higher annual earnings (EBITDA): 89.3M vs. BBIO (-643.59M). ONC has more cash in the bank: 2.76B vs. BBIO (757M). ONC has less debt than BBIO: ONC (1.03B) vs BBIO (1.86B). ONC has higher revenues than BBIO: ONC (4.56B) vs BBIO (236M).
BBIOONCBBIO / ONC
Capitalization10.5B35.3B30%
EBITDA-643.59M89.3M-721%
Gain YTD100.14671.306140%
P/E RatioN/AN/A-
Revenue236M4.56B5%
Total Cash757M2.76B27%
Total Debt1.86B1.03B181%
FUNDAMENTALS RATINGS
BBIO vs ONC: Fundamental Ratings
BBIO
ONC
OUTLOOK RATING
1..100
959
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
8184
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
4046
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a16

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (4) in the null industry is somewhat better than the same rating for ONC (49) in the Biotechnology industry. This means that BBIO’s stock grew somewhat faster than ONC’s over the last 12 months.

BBIO's Profit vs Risk Rating (81) in the null industry is in the same range as ONC (84) in the Biotechnology industry. This means that BBIO’s stock grew similarly to ONC’s over the last 12 months.

ONC's SMR Rating (94) in the Biotechnology industry is in the same range as BBIO (100) in the null industry. This means that ONC’s stock grew similarly to BBIO’s over the last 12 months.

BBIO's Price Growth Rating (40) in the null industry is in the same range as ONC (46) in the Biotechnology industry. This means that BBIO’s stock grew similarly to ONC’s over the last 12 months.

BBIO's P/E Growth Rating (100) in the null industry is in the same range as ONC (100) in the Biotechnology industry. This means that BBIO’s stock grew similarly to ONC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBIOONC
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 19 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BHV11.230.43
+4.03%
BlackRock Virginia Muni
VYLD26.440.43
+1.64%
Inverse Vix Short-Term Futures Etns Due March 22, 2045
FMDE35.400.12
+0.34%
Fidelity Enhanced Mid Cap ETF
GXC100.99-0.46
-0.45%
SPDR® S&P China ETF
IDNA24.61-0.18
-0.72%
iShares Genomics Immnlgy & Hlthcr ETF

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with IRON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then IRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
-0.20%
IRON - BBIO
44%
Loosely correlated
+20.95%
AXON - BBIO
44%
Loosely correlated
+2.84%
ARRY - BBIO
43%
Loosely correlated
-0.17%
PMN - BBIO
43%
Loosely correlated
-6.22%
XENE - BBIO
42%
Loosely correlated
-1.28%
More